Advancing CAR T-cell Therapy in Difficult to Treat Cancers: An Interview with Precigen’s Helen Sabzevari

Advancing CAR T-cell Therapy in Difficult to Treat Cancers: An Interview with Precigen’s Helen Sabzevari

2 0 hace 7 meses
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen.

Precigen is a biopharmaceutical company dedicated to the discovery and clinical-stage development of the next generation of gene and cell therapies using precision technology. The company is developing novel therapeutic agents that are designed to target the most urgent and difficult diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

During the second ... Más informaciones

Síguenos en Facebook